INTRODUCTION
Fibroblasts accumulate at sites of tissue injury and inflammation and effect repair by synthesizing new connective tissue elements (collagen, fibronectin, and glycosaminoglycans). The realization that fibroblasts participate in virtually all types of inflammatory lesions has prompted us to look for different sources of chemoattractants for these specialized effector cells. We have recently developed an assay that measures human fibroblast chemotaxis in vitro (1) .
Thus far, two different types of fibroblast chemoattractants have been recognized, (a) a lymphokine with a 22,000 mol wt produced by antigen-or mitogenstimulated human peripheral blood lymphocytes, and (b) collagen and collagen-derived peptides (1) (2) (3) Received for publication 7 September 19977 and in revised form 21 June 1979. In this report we have examined human serum as a possible source of a chemoattractant for fibroblasts. Normal human serum itself is not chemotactic for fibroblasts. However, activation of either the classical or alternative pathways of complement in serum is accompanied by production of a factor that is chemotactic for fibroblasts. Characterization studies suggest that this factor may be derived from the fifth component of complement.
METHODS
Fibroblast chemotaxis assay. Human dermal fibroblasts obtained from punch biopsy of the skin of adults and maintained in monolayer cultures served as responding cells in the in vitro chemotaxis assay. Details regarding the methods employed in maintaining the cultures and harvesting the fibroblasts by trypsinization for use in the assay have been given in a previous report (1) . Blind-well modified Boyden chemotaxis chambers (Duke University Surgical Instrument Shop, Durham, N. C.) were used to measure fibroblast chemotaxis. Polycarbonate filters with 8-,um pores were used in the chemotaxis chambers. Before being used in the assay, filters were treated with a dilute gelatin solution to change surface properties to facilitate fibroblast adherence, as previously described (1) .
Substances being tested for fibroblast chemotactic activity (CTX)l were brought up to a volume of 0.4 ml with 0.015 M glycylglycine/0.14 M NaCl (GGBS) at pH 7.2 and were mixed with 0.35 ml of Eagle's minimum essential medium (MEM) supplemented with nonessential amino acids, ascorbic acid (50 .ggml), and streptomycin (100 p,g/ml). Ali(luots (0.2 ml) of this mixture were loaded into the lower compartment of the chemotaxis chambers. Prepared polyearbonate filters (dull side up) were placed over the lower compartments. The chambers were assembled, and the upper compartments were filled with fibroblasts suspended at a concentration of 2.5 x 105 cells/ml of serum-free MEM.
' Abbreviations used in this paper: CTX, chemotactic activity; GGBS, 0.015 M glycylglycine/0.14 M NaCl; HAGG, heat-aggregated human gamma globulin; LPS, lipopolysaccharide; MEM, minimum essential medium; SDCF, serumderived chemotactic factor.
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Loaded chambers were placed in a humidified incubator in an atmosphere that contained 5% CO2 at 37°C for 150 min. After incubation, the filters were removed, stained with hematoxylin, and mounted on glass slides as described previously (1) . Fibroblast CTX was quantitated by counting in 20 oil immersion fields (magnification: 1,000) nuclei of fibroblasts that migrated to the lower surface of the filters. All samples were assayed in triplicate, and final activity was expressed where indicated as the mean±SEM of the replicates.
Monocyte chemotaxis assay. Human monocyte chemotaxis was measured with blind-well modified Boyden chemotaxis chambers equipped with polycarbonate filters with 5-,um pores (Wallabs, Inc., San Rafael, Calif) by methods previously described (4, 5) .
Neutrophil chemotaxis assay. Human neutrophil chemotaxis was quantitated with blind-well modified Boyden chemotaxis chambers equipped with polycarbonate filters with 3-,um pores (Bio-Rad Laboratories, Richmond, Calif.) as previously described (4 Serum (2.5 ml) was incubated with 1.25 ml of 0.9% NaClcontaining zymosan (11.2 mg) for 1 h at 37°C, and applied to the G-150 column. Gel filtration was performed at 4°C, and the column effluent was continuously monitored for absorbance at 280 nm with a Uvicord III recording spectrophotometer (LKB Instruments, Inc., Rockville, Md.).
Ion exchange chromatography. A column 2.5 cm in diameter and 60 cm in length was packed with DEAESephadex A-50 equilibrated with 0.0075 M glycylglycine/ 0.01 M NaCl at pH 8.0. Fractions (67 ml, containing 56 mg of protein) from gel filtration of zymosan-activated serum that contained fibroblast CTX were dialyzed against this same buffer and loaded onto the column. The column was washed with the buffer until the optical density of the effluent returned to the base line. The absorbed proteins were eluted from the column by a linear salt gradient at 4°C with 0.0075 M glycylglycine/1.0 M NaCl, pH 8.0, as the limiting buffer. Eluted fractions were dialyzed extensively against GGBS at pH 7.2. Volumes ofdialyzed fractions were equalized by adding GGBS as necessary, and aliquots of each fraction were assayed for fibroblast CTX.
Antisera to human C3 and C5. Goat anti-human C3 and anti-human C5 were purchased from Meloy Laboratories Inc. (Springfield, Va.). The antisera were dialyzed at 40C against GGBS to remove preservatives.
Treatment offibroblast chemotactic factor with insoluble trypsin. It was of interest to determine what effect trypsin would have on the biologic activity of the fibroblast chemotactic factor. Normal serum was treated with zymosan and fractionated on Sephadex G-150 as described above.
Fractions from the region of the chromatogram with maximal fibroblast CTX were pooled. Aliquots (1 ml) of the pooled fractions were mixed with 0.680 U of trypsin conjugated to polyacrylamide beads (Sigma Chemical Co.). The beads were preswollen and washed with RPMI 1640 medium before they were added to aliquots of the column fractions. Samples were incubated for 0-120 min with the trypsin-polyacrylamide conjugate at 300C. After incubation, the trypsin-polyacrylamide conjugate was removed from samples by centrifugation at 400 g at 4°C. Samples were then tested for fibroblast CTX.
RESULTS
Generation of fibroblast CTX by complement activators. In preliminary studies, the ability of fresh normal human serum to act as a chemoattractant for human fibroblasts was evaluated. Fibroblasts did not recognize normal serum as a chemotactic stimulus at concentrations ranging from 1 to 50% (data omitted).
Serum complement was activated by HAGG, zymosan, and LPS to determine whether such treatment would lead to the generation of fibroblast CTX. When serum was incubated with HAGG, zymosan, or LPS for 1 h at 37°C and then heated to 56°C for 30 min it became chemotactic for fibroblasts (Table I) . Incubation ofserum with saline produced minimal stimulation of fibroblast migration that was approximately twofold greater than that observed with saline alone (Table I) . If serum were heated to 56°C for 30 min before being incubated with the activators, only minimal fibroblast CTX was generated (Table I) . The activators, when incubated with saline, were not chemotactic for fibroblasts (Table I) . These data are consistent with the notion that serum-derived chemotactic factor (SDCF) for fibroblasts is derived from a complement component or is generated when complement is activated. Molecular sieve chromatography. In an effort to determine the molecular weight of SDCF, zymosanactivated serum was fractionated on Sephadex G-150, and column fractions were assayed for fibroblast CTX. A major peak ofCTX eluted from the column in advance of the albumin peak (Fig. 1) . Based on this elution profile, the molecular weight of SDCF is calculated to be _80,000. In additional gel filtration studies not shown, we found that activation of serum complement by HAGG or LPS was associated with production of a similar size chemotactic factor for fibroblasts, but no chemotactic factor for fibroblasts was found when 1380
A. E. Postlethwaite, R. Snyderman, and A. H. Kang were not chemotactic for monocytes or neutrophils (Table II) . As expected, the major amount of chemotactic activity for monocytes and neutrophils was found in a column fraction from the 15,000-mol wt peak that contained C5a (Table II) . Although the column fraction that contained C5a was chemotactic for monocytes and neutrophils, it was not chemotactic for fibroblasts (Table II) . Ion exchange chromatography. SDCF recovered from Sephadex G-150 was further purified by ion exchange chromatography. Fractions that contained SDCF from two column runs of zymosan-activated serum were pooled together and passed through a column packed with DEAE-Sephadex A-50 (Fig. 2) . Retained proteins were eluted from the column by a linear gradient of NaCl. A small amount of CTX was found in the major protein peak, but the majority of activity eluted from the column after most of the proteins when the conductivity of the eluting buffer was between 8 and 12 mMHO (Fig. 2) . SDCF recovered from this ion exchange column was used in additional characterization studies. were added to the upper and/or lower compartments of the chemotaxis chambers, and fibroblast migration to the lower filter surface was determined (Table III) (Table IV) . All six fibroblast lines migrated in response to the SDCF (Table IV) . This suggests that all human dermal fibroblasts recognize SDCF as a chemotactic stimulus.
Chemotactic response offibroblasts dispersed with EDTA. Trypsin may alter plasma membrane recep- (7, 8) . The use of trypsin to harvest fibroblasts from monolayer cultures could theoretically alter the plasma membrane and expose an artificial receptor for SDCF. Therefore, it was essential to determine whether fibroblasts harvested with EDTA would respond chemotactically to SDCF. Fibroblasts grown in monolayer culture were dispersed with 5 mM EDTA so as not to alter surface membrane receptors. Fibroblasts harvested in this manner also migrated in response to the SDCF (data omitted), which suggests that the membrane recognition site for the factor is readily accessible and does not have to be uncovered or altered by trypsin. Treatment of SDCF with anti-C3 and anti-C5 antisera. The generation of fibroblast CTX in serum by agents that activate the complement sequence suggested that the factor might be derived from a complement component. Because cleavage products from C3 and C5 have been reported to be chemotactic for leukocytes (5, 9-11), we wondered whether the fibroblast chemotactic factor might also be derived from either of these complement components. If C3 or C5 were the source of SDCF, then monospecific antiserum to these respective complement components might block its ability to act as a chemoattractant for fibroblasts. To explore this issue, aliquots (0.3 ml) of SDCF, obtained from fractionation of zymosantreated serum by Sephadex G-150, were incubated with 0.05 ml of monospecific goat anti-human C3 or anti-human C5 antisera. Fibroblast CTX in treated and untreated samples was determined. The anti-C5-treated SDCF elicited no migration of fibroblasts (Table V) . In contrast, anti-C3-treated SDCF retained CTX (Table V) . As a control for nonspecific inhibition of fibroblast migration by the anti-C5 antiserum, collagen, a chemoattractant for fibroblasts, was incubated with the antiserum. The antiserum did not reduce migration of fibroblasts to collagen (Table V) .
These data suggest that the SDCF generated by activators of complement share antigenic determinants in common with C5.
Inability of C5-deficient serum to generate SDCF. Because data obtained by the use of antisera suggested that the fibroblast chemotactic factor might be derived from C5, it was important to determine whether "activated" sera from subjects with C5 deficiency contained CTX for fibroblasts. Sera were obtained from two siblings with proven C5 deficiency and from two normal, control donors (12) . Aliquots of each serum sample were incubated with saline, HAGG, or LPS and assayed for fibroblast CTX. Fibroblast CTX was not detectable in HAGG-or LPS-treated sera from the C5- deficient subjects (Table VI) . Chemotactic activity for fibroblasts was generated in the normal sera by these complement activators (Table VI) . These results suggest that SDCF is derived from C5 or that C5 is necessary for generation of SDCF. Effect of trypsin on SDCF. It was of interest to determine whether SDCF was a protein. Treatment of DEAE-Sephadex-purified SDCF with trypsin at 30°C resulted in destruction of fibroblast CTX (Table VII) . These data suggest that an intact protein structure is essential for fibroblast CTX to be expressed by SDCF. DISCUSSION Activation of serum complement by classical or alternative pathways is accompanied by generation ofa trypsinsensitive protein with an apparent 80,000 mol wt that is chemotactic for human dermal fibroblasts in vitro. Several lines of evidence suggest that SDCF might be derived from the 5th component ofcomplement. Chemotactic migration of fibroblasts to the factor is negated if it is preincubated with monospecific anti-C5 antiserum. This indicates that SDCF is either C5 derived or has antigenic similarity to C5. The factor is not generated when sera from patients genetically deficient in C5 are treated with endotoxin or HAGG. This suggests that the presence of C5 in human serum is essential for generation of SDCF.
Whereas SDCF has not been purified to homogeneity in this study, a combination of gel filtration and ion exchange chromatography effectively separated SDCF Serum-derived Chemotactic Factor for Fibroblasts 
